ExploreWatchlistsPricing
  1. JP-listed companies
  2. SEIKAGAKU CORPORATION
  3. Financials
  4. Cash from operations

SEIKAGAKU CORPORATION (4548)

Market cap
¥42.8B
P/E ratio
45.7x
Develops and manufactures pharmaceuticals for joint care, eye surgery, and spinal treatments, plus specialized LAL testing reagents that ensure drug safety.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndCash from operations (Million JPY)YoY (%)
Mar 31, 20254,429+763.35%
Mar 31, 2024513-67.41%
Mar 31, 20231,574-80.79%
Mar 31, 20228,192+551.71%
Mar 31, 20211,257-85.50%
Mar 31, 20208,670+177.80%
Mar 31, 20193,121-41.62%
Mar 31, 20185,346+9.44%
Mar 31, 20174,885-12.69%
Mar 31, 20165,595+35.41%
Mar 31, 20154,132

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat